• Bradford Protein Assay Kit: Rapid, Sensitive Protein Quantif

  2026-04-26

  The Bradford Protein Assay Kit (SKU K4103) offers a streamlined, sensitive solution for determining protein concentration in biochemical research samples. It is best applied in workflows requiring rapid throughput and routine quantification, but is not optimal for samples with interfering substances or for absolute protein purity assessment.

• Accelerated HepaRG Differentiation Enables Rapid HBV/HDV Stu

  2026-04-25

  Lucifora et al. developed a fast differentiation protocol for HepaRG cells, allowing efficient Hepatitis D virus infection within one week, a significant improvement over the standard four-week method. This advancement streamlines studies of virus-host interactions but highlights unresolved barriers to robust Hepatitis B virus replication.

• FITC Goat Anti-Mouse IgG (H+L) Antibody: Boosting Immunofluo

  2026-04-24

  Leverage the FITC Goat Anti-Mouse IgG (H+L) Antibody for superior sensitivity and signal amplification in both immunofluorescence and flow cytometry. This APExBIO reagent streamlines mouse IgG detection with robust performance, reproducibility, and optimized workflow flexibility.

• Targeted Demethylation of BRD7 Suppresses NPC Progression

  2026-04-24

  This study demonstrates that CRISPR/dCas9-TET1CD-mediated demethylation of the BRD7 promoter restores BRD7 expression and impedes nasopharyngeal carcinoma (NPC) progression. These findings highlight the therapeutic potential of locus-specific epigenetic editing for tumor suppressor gene reactivation in solid tumors.

• C-Terminal Mutations in VZV gE Enhance mRNA Vaccine Immunity

  2026-04-23

  This study investigates how specific carboxyl-terminal mutations in varicella-zoster virus glycoprotein E (gE) affect the efficacy of mRNA vaccines. The results demonstrate that targeted double mutations in the gE C-terminus significantly improve both humoral and cellular immune responses, offering a promising strategy for next-generation zoster and varicella mRNA vaccines.

• Tivozanib (AV-951): Precision VEGFR Inhibition in Oncology R

  2026-04-23

  Tivozanib (AV-951) delivers industry-leading selectivity and potency for anti-angiogenic therapy, setting a new benchmark for renal cell carcinoma treatment and advanced in vitro assay design. This article translates recent experimental innovations and troubleshooting insights into actionable lab strategies for maximizing Tivozanib’s translational impact.

• Antibiotic Use and Resistance in Psychiatric Hospitals Durin

  2026-04-22

  This study provides a comprehensive retrospective analysis of antibacterial drug use and bacterial resistance patterns in a psychiatric hospital during the 2022 COVID-19 epidemic. Findings reveal that, while overall antibiotic usage was lower than regional and national averages, resistance rates among both Gram-negative and Gram-positive bacteria remain a significant concern, highlighting the need for continued surveillance and optimization of antimicrobial protocols.

• Deep Learning Reveals Cardiotoxicity in iPSC-CM Drug Screens

  2026-04-22

  Grafton et al. present a scalable deep learning approach for detecting cardiotoxicity in high-content screens using iPSC-derived cardiomyocytes. This method enables early and sensitive identification of cardiotoxic compounds, guiding safer drug development.

• Coptisine Modulates SIRT1 Ubiquitination to Ameliorate PCOS

  2026-04-21

  This study elucidates how Jiao-tai-wan (JTW) and its active alkaloid, coptisine, improve polycystic ovary syndrome (PCOS) in DHEA-induced rat models by regulating mitochondrial cholesterol import through SIRT1 deubiquitination. The findings clarify molecular mechanisms linking herbal therapy, mitochondrial function, and ovarian steroidogenesis, offering new targets for PCOS intervention.

• Bufuralol Hydrochloride: Advancing β-Adrenergic Modulation S

  2026-04-21

  Bufuralol hydrochloride empowers cardiovascular pharmacology and β-adrenergic modulation studies with robust performance in organoid and animal models. Its partial sympathomimetic activity and proven reliability, especially in humanized pharmacokinetic workflows, make it an indispensable tool for translational research.

• KPT330 Enhances CRISPR-Cas9 Editing Specificity via mRNA Exp

  2026-04-20

  This study uncovers a novel mechanism for improving the specificity of CRISPR-Cas9 genome and base editing by using KPT330, a selective inhibitor of nuclear export (SINE). By targeting the nuclear export of Cas9 mRNA rather than the protein directly, the approach represents a significant advancement in minimizing off-target effects and increasing editing precision in mammalian cells.

• Substance P Protocols: Parameters & QC for Tachykinin Resear

  2026-04-20

  Substance P (SKU B6620) provides a high-purity tachykinin neuropeptide for dissecting neurokinin-1 receptor pathways in pain transmission, inflammation, and immune response studies. It is best suited for workflows requiring rapid solution use, high water solubility, and precise control of peptide quality, but is not recommended where long-term solution stability or DMSO/ethanol solubility is necessary.

• High-Throughput BBB Model Enhances CNS Drug Screening Accura

  2026-04-19

  This study introduces a validated in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells, enabling high-throughput and accurate prediction of CNS drug permeability. By integrating lysosomal trapping correction, the model demonstrates strong correlation with in vivo brain distribution, streamlining early-stage neurological drug development.

• CX-5461 Induces DNA Damage and Sensitizes Cervical Cancer Ce

  2026-04-18

  The referenced study demonstrates that the RNA polymerase I inhibitor CX-5461 suppresses cervical cancer cell growth by inducing DNA damage and mitotic catastrophe, offering a mechanistically distinct approach to overcoming chemoresistance. These findings expand the therapeutic rationale for targeting ribosome biogenesis in aggressive and treatment-resistant cervical cancer.

• Structural Basis for HCAR3 Agonist Selectivity in Lipid Meta

  2026-04-17

  This study elucidates the high-resolution cryo-EM structures of the G-protein coupled receptor HCAR3 in complex with selective agonists, including Acifran. The findings reveal the molecular determinants responsible for ligand recognition and selectivity, providing a foundation for the rational design of hypolipidemic agents with improved specificity.

447 records 20/30 page Previous Next First page 上5页 1617181920 下5页 Last page